IL4 and atopic eczema: Notably, dupilumab’s mechanism of action overlaps with the inflammatory pathways involved in atopic comorbidities, such as atopic dermatitis, allergic rhinitis, and chronic rhinosinusitis with nasal polyps, all of which are associated with elevated levels of IL-4 and IL-13 cytokines (Pelaia et al., 2022).